Sort
130,381 grants matching “hiv”
Inhibition of HIV at the Immune Synapse Utilizing Novel Ligands and Receptors
$841,500Jerome E Groopman · Beth Israel Deaconess Medical Center · DP1 · FY2010 · DA
Targeting the HIV/SIV reservoir at time of ART initiation
$841,447Afamefuna Okoye · Oregon Health & Science University · R01 · FY2023 · AI
Host Genetic Determinants of HIV Pathogenesis
$841,436Sunil K Ahuja · University Of Texas Hlth Science Center · R37 · FY2009 · AI
A Novel, Multi-compartment Intravaginal Ring for Prevention of Genital Herpes and Unintended Pregnancy
$841,397Marc Michael Baum · Oak Crest Institute Of Science · R01 · FY2024 · AI
Drug Abuse Treatment System Survey
$841,359Jeffrey A Alexander · University Of Michigan At Ann Arbor · R01 · FY2006 · DA
Maximizing germinal centers and somatic hypermutation to HIV Env immunogens
$841,326Shane P Crotty · La Jolla Institute For Immunology · R01 · FY2018 · AI
Low Cost Multi-pathogen Laser Diagnostic for HIV and AIDS Co-Infections
$841,216Christopher John Myatt · Precision Photonics Corporation (Ppc) · R44 · FY2009 · AI
PRIDEnet for the All of Us Research Program
$841,192Mitchell Ryan Lunn · Stanford University · OT2 · FY2023 · OD
NIDA Epidemiology Training Program
$841,140Renee M. Johnson · Johns Hopkins University · T32 · FY2015 · DA
Impact of HIV Envelope Conformation on Immunogenicity
$841,137Dan H. Barouch · Beth Israel Deaconess Medical Center · R01 · FY2010 · AI
Elucidating the Molecular Mechanisms that Mediate DKD Progression in Patients Living with HIV
$841,127John C He · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · DK
Elucidating the Molecular Mechanisms that Mediate DKD Progression in Patients Living with HIV
$841,127John C He · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · DK
Immunomodulatory Effects of IL-7 in Primate Immunodeficiency Virus Infections
$841,055Paolo Lusso · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI
Effect of obesity on HIV pathogenesis, antiretroviral therapy, and metabolic comorbidities
$841,023Charles T Roberts · Oregon Health & Science University · R01 · FY2021 · DK
Identifying correlates of risk for future tuberculosis disease progression in children (INTREPID)
$840,947James Alexander Seddon · Stellenbosch University · R01 · FY2023 · AI
Alphavirus Replicon Vaccines to Encephalitis Viruses
$840,848Alphavax Human Vaccines, Inc. · U01 · FY2003 · AI
Avoiding (Heart) Failure: Physiologic-Based Targeting of the RAAS to Treat Subclinical HFpEF among PWH
$840,829Suman Srinivasa · Massachusetts General Hospital · R01 · FY2024 · HL
Project 2
$840,818Hanneke Schuitemaker · Beth Israel Deaconess Medical Center · U19 · FY2021 · AI
PD-1 blockade as a therapy for SIV/AIDS
$840,757Rama Rao Amara · Emory University · R01 · FY2010 · AI
Germline-Specific Immunogens for the Induction of Neutralizing Antibodies to HIV-
$840,676Robert Gerald Whalen · Altravax, Inc. · R01 · FY2014 · AI
Mechanisms Of Humoral Evasion
$840,558Peter D Kwong · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI
Protective Immunity
$840,487David I Watkins · University Of Miami School Of Medicine · P01 · FY2015 · AI
Development of an mRNA-Based Therapeutic HIV/AIDS Vaccine
$840,477Afamefuna Okoye · Oregon Health & Science University · R01 · FY2023 · AI
EARLY AND REINFECTION IN HIGH RISK WOMEN
$840,402Julie M Overbaugh · Fred Hutchinson Cancer Research Center · R37 · FY2010 · AI
3BNC117 mAb in HIV-infected subjects on combination ART
$840,281Marina Caskey · Rockefeller University · U01 · FY2015 · AI